Ascendis Pharma Statistics
Total Valuation
Ascendis Pharma has a market cap or net worth of $9.53 billion. The enterprise value is $9.82 billion.
Important Dates
The next estimated earnings date is Monday, May 5, 2025, after market close.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Ascendis Pharma has 60.12 million shares outstanding. The number of shares has increased by 2.85% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 60.12M |
| Shares Change (YoY) | +2.85% |
| Shares Change (QoQ) | +3.91% |
| Owned by Insiders (%) | 0.78% |
| Owned by Institutions (%) | 83.85% |
| Float | 59.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 24.32 |
| Forward PS | 16.50 |
| PB Ratio | -86.88 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 26.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.17
| Current Ratio | 1.17 |
| Quick Ratio | 0.81 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.26 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -17.38% |
| Return on Invested Capital (ROIC) | -27.89% |
| Return on Capital Employed (ROCE) | -102.63% |
| Revenue Per Employee | $370,186 |
| Profits Per Employee | -$384,889 |
| Employee Count | 1,017 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 0.18 |
Taxes
In the past 12 months, Ascendis Pharma has paid $5.01 million in taxes.
| Income Tax | 5.01M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +11.51% in the last 52 weeks. The beta is 0.54, so Ascendis Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +11.51% |
| 50-Day Moving Average | 152.25 |
| 200-Day Moving Average | 137.53 |
| Relative Strength Index (RSI) | 55.10 |
| Average Volume (20 Days) | 570,989 |
Short Selling Information
| Short Interest | 4.31M |
| Short Previous Month | 4.38M |
| Short % of Shares Out | 8.62% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 9.75 |
Income Statement
In the last 12 months, Ascendis Pharma had revenue of $376.48 million and -$391.43 million in losses. Loss per share was -$6.76.
| Revenue | 376.48M |
| Gross Profit | 330.66M |
| Operating Income | -288.60M |
| Pretax Income | -539.03M |
| Net Income | -391.43M |
| EBITDA | -283.50M |
| EBIT | -288.60M |
| Loss Per Share | -$6.76 |
Full Income StatementBalance Sheet
The company has $579.30 million in cash and $886.86 million in debt, giving a net cash position of -$307.56 million or -$5.12 per share.
| Cash & Cash Equivalents | 579.30M |
| Total Debt | 886.86M |
| Net Cash | -307.56M |
| Net Cash Per Share | -$5.12 |
| Equity (Book Value) | -109.44M |
| Book Value Per Share | -1.83 |
| Working Capital | 158.40M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$317.01 million and capital expenditures -$1.48 million, giving a free cash flow of -$348.53 million.
| Operating Cash Flow | -317.01M |
| Capital Expenditures | -1.48M |
| Free Cash Flow | -348.53M |
| FCF Per Share | -$5.80 |
Full Cash Flow StatementMargins
Gross margin is 87.83%, with operating and profit margins of -76.66% and -103.97%.
| Gross Margin | 87.83% |
| Operating Margin | -76.66% |
| Pretax Margin | -102.64% |
| Profit Margin | -103.97% |
| EBITDA Margin | -75.30% |
| EBIT Margin | -76.66% |
| FCF Margin | n/a |
Dividends & Yields
Ascendis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.85% |
| Shareholder Yield | -2.85% |
| Earnings Yield | -4.12% |
| FCF Yield | -3.67% |
Dividend DetailsAnalyst Forecast
The average price target for Ascendis Pharma is $202.00, which is 27.48% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $202.00 |
| Price Target Difference | 27.48% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 45.47% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ascendis Pharma has an Altman Z-Score of 0.04 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.04 |
| Piotroski F-Score | 4 |